Vital sign and physical distress monitoring

The manuals converge on routine monitoring of vital signs as a core safety activity during study visits or dosing periods. Across the extracts, they recommend tracking blood pressure and heart rate or pulse, watching for acute physiological change, and linking vital sign review with broader adverse event or medical monitoring. Several sources also connect abnormal findings with escalation to a clinician or investigator, showing a shared emphasis on recognising instability rather than treating vital signs as isolated measurements. They also overlap in attention to participant comfort and symptomatic distress. The ClinicalTrials.gov protocol explicitly includes dizziness, nausea, fatigue, headache, and breaks or comfort measures, while the other sources focus more narrowly on haemodynamic observation and response to changing vital signs. This means the common ground is not only numerical monitoring, but also observing how participants are physically tolerating the session. The manuals differ in how specific and intensive the monitoring is. The ibogaine case report describes continuous nursing observation and at least hourly heart rate and blood pressure checks, while the observational ibogaine study refers to repeated interval-based assessment and attention to QTc-related clinical significance. By contrast, the 5-MeO-DMT source is broader, describing vital sign monitoring during and after administration and follow-up as indicated, without the same level of frequency or named parameters beyond vital signs in general.